Skip to main content
SpringerLink
Log in

Breast

  • Chapter
Cancer Precursors

Conclusions

Experimental and epidemiological evidence supports the notion that benign proliferative epithelial disorders of the breast are precursors of breast cancer: experimental models have shown that proliferative lesions progress to breast cancer, and epidemiological studies have shown that the peak incidence rate for benign breast disease occurs 15 to 20 years before that for breast cancer [2], and that women with proliferative forms of benign breast disease are at increased risk of breast cancer. Nevertheless, the precise nature of the relationship between the two conditions remains uncertain. From the available evidence, it would appear that there are two possibilities: either benign proliferative epithelial disorders of the breast progress to breast cancer, or the benign lesions and breast cancer might be independent outcomes resulting from the action on breast tissue of (at least partially) overlapping sets of etiological factors [166]. In either case, as indicated earlier, risk factors for benign proliferative epithelial disorders of the breast should be a subset of those for breast cancer. The currently available epidemiological evidence provides some support for the notion that benign proliferative epithelial disorders and breast cancer do share risk factors, but further study of risk factors for benign proliferative epithelial disorders of the breast, although important in elucidating the etiology of these conditions, seems unlikely to resolve the issue of whether or not they truly are precursors of breast cancer. In this regard, recent and ongoing molecular studies might help if they can demonstrate that breast cancers represent clonal outgrowths of pre-existing benign lesions. However, such studies are still in their infancy. Finally, if risk factors for benign proliferative epithelial disorders of the breast are indeed a subset of those for breast cancer, and if these benign conditions do progress to breast cancer, then factors other than those responsible for the development of the benign conditions should influence their progression to breast cancer. Hence, it may be of interest to study risk factors for breast cancer in women with benign proliferative epithelial disorders of the breast.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hislop TG, Elwood MJ. Risk factors for benign breast disease: a 30-year cohort study. Can Med Assoc J 1981; 124:283–91.

    PubMed  CAS  Google Scholar 

  2. Fleming NT, Armstrong BK, Sheiner HJ. The comparative epidemiology of benign breast lumps and breast cancer in Western Australia. Int J Cancer 1982; 30:147–51.

    PubMed  CAS  Google Scholar 

  3. Bodian CA. Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol Rev 1993; 15:177–87.

    PubMed  CAS  Google Scholar 

  4. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987.

    Google Scholar 

  5. Schwartz GF, Lagios MD, Carter D, et al. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 1997; 28:1221–4.

    Google Scholar 

  6. Miller FR, Soule HD, Tait L, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 1993; 85: 1725–32.

    PubMed  CAS  Google Scholar 

  7. Davies BR, Platt-Higgins AM, Schmidt G, et al. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TFF transgenic rats. Am J Pathol 1999; 155:303–14.

    PubMed  CAS  Google Scholar 

  8. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000; 19:1002–9.

    PubMed  CAS  Google Scholar 

  9. Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985; 6:5–36.

    Article  PubMed  CAS  Google Scholar 

  10. Fitzgibbons PL, Henson DE, Hutter RVP. Benign breast changes and risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998; 122:1053–5.

    PubMed  CAS  Google Scholar 

  11. Cook MG, Rohan TE. The patho-epidemiology of benign proliferative epithelial disorders of the female breast. J Pathol 1985; 146:1–15.

    Article  PubMed  CAS  Google Scholar 

  12. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomark Prev 1996; 5:29–32.

    CAS  Google Scholar 

  13. Page DL, Jensen RA, Simpson JF. Premalignant and malignant disease of the breast: the role of the pathologist. Mod Pathol 1998; 11: 120–8.

    PubMed  CAS  Google Scholar 

  14. Page DL, Kidd TE, Dupont WD, et al. Lobular neoplasia of the breast. Hum Pathol 1991; 22: 1232–9.

    PubMed  CAS  Google Scholar 

  15. Webber W, Boyd N. A critique of the methodology of studies of benign breast disease and breast cancer risk. J Natl Cancer Inst 1986; 77:397–404.

    PubMed  CAS  Google Scholar 

  16. Davis HH, Simons M, Davis JB. Cystic disease of the breast: relationship to carcinoma. Cancer 1964; 17:957–78.

    PubMed  CAS  Google Scholar 

  17. Black MM, Barclay THC, Cutler SJ, et al. Association of atypical characteristics of benign breast lesion with subsequent risk of breast cancer. Cancer 1972; 29:338–43.

    PubMed  CAS  Google Scholar 

  18. Donnelly PK, Baker KW, Carney JA, et al. Benign breast lesions and subsequent breast carcinoma in Rochester, Minnesota. Mayo Clin Proc 1975; 50:650–6.

    PubMed  CAS  Google Scholar 

  19. Devitt JE. Breast cancer and preceding clinical benign breast disorders. A chance association. Lancet 1976; i:793–5.

    Google Scholar 

  20. Monson RR, Yen S, MacMahon B, et al. Chronic mastitis and carcinoma of the breast. Lancet 1976; ii:224–6.

    Google Scholar 

  21. Kodlin D, Winger EE, Morgenstern NL, et al. Chronic mastopathy and breast cancer: a follow-up study. Cancer 1977; 39:2603–7.

    PubMed  CAS  Google Scholar 

  22. Page DL, Vander Zwag R, Rogers LW, et al. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 1978; 61:1055–63.

    PubMed  CAS  Google Scholar 

  23. Coombs LJ, Lilienfeld AM, Bross ID, et al. A prospective study of the relationship between benign breast diseases and breast carcinoma. Prev Med 1979; 8:40–52.

    PubMed  CAS  Google Scholar 

  24. Moskowitz M, Gartside P, Wirman JA, et al. Proliferative disorders of the breast as risk factors for breast cancer in a self-selected population: pathologic markers. Radiology 1980; 134:289–91.

    PubMed  CAS  Google Scholar 

  25. Hutchinson WB, Thomas DB, Hamlin WB, et al. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst 1980; 65:13–20.

    PubMed  CAS  Google Scholar 

  26. Devitt JE. Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet 1981; 152:437–40.

    PubMed  CAS  Google Scholar 

  27. Roberts MM, Jones V, Elton RA, et al. Risk of breast cancer in women with history of benign disease of the breast. Br Med J 1984; 288: 275–8.

    CAS  Google Scholar 

  28. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146–51.

    PubMed  CAS  Google Scholar 

  29. Carter CL, Corle DK, Micozzi MS, et al. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988; 128:467–77.

    PubMed  CAS  Google Scholar 

  30. Ris H-B, Niederer U, Stirnemann H, et al. Long-term follow-up of patients with biopsy proven benign breast disease. Ann Surg 1988; 207:404–9.

    PubMed  CAS  Google Scholar 

  31. Palli D, del Turco MR, Simoncini R, et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991; 47:703–6.

    PubMed  CAS  Google Scholar 

  32. London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267:941–4.

    Article  PubMed  CAS  Google Scholar 

  33. McDivitt RW, Stevens JA, Lee NC, et al. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992; 69:1408–14.

    PubMed  CAS  Google Scholar 

  34. Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases. Am J Epidemiol 1992; 135:619–31.

    PubMed  CAS  Google Scholar 

  35. Nomura Y, Tashiro H, Katsuda Y. Benign breast disease as a breast cancer risk in Japanese women. Jpn J Cancer Res 1993; 84:938–44.

    PubMed  CAS  Google Scholar 

  36. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71:128–65.

    Google Scholar 

  37. Bodian CA, Perzin KH, Lattes R, et al. Prognostic significance of benign proliferative breast disease. Cancer 1993; 71:3896–907.

    PubMed  CAS  Google Scholar 

  38. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997; 6:297–301.

    PubMed  CAS  Google Scholar 

  39. Minami Y, Ohuchi N, Taeda Y, et al. Risk of breast cancer in Japanese women with benign breast disease. Jpn J Cancer Res 1999; 90:600–6.

    PubMed  CAS  Google Scholar 

  40. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985; 55:2698–708.

    PubMed  CAS  Google Scholar 

  41. Levi F, Randimbison L, Te V-C, et al. Incidence of breast cancer in women with fibroadenoma. Int J Cancer 1994; 57:681–3.

    PubMed  CAS  Google Scholar 

  42. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994; 331:10–15.

    Article  PubMed  CAS  Google Scholar 

  43. Ciatto S, Bonardi R, Zappa M, et al. Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma-retrospective longitudinal study of 3938 cases. Ann Oncol 1997; 8:297–300.

    Article  PubMed  CAS  Google Scholar 

  44. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989; 20:723–5.

    Article  PubMed  CAS  Google Scholar 

  45. Connolly J, Schnitt S, London S, et al. Both atypical lobular hyperplasia (ALH) and atypical ductal hyperplasia (ADH) predict for bilateral breast cancer risk. Lab Invest 1992; 66:13A.

    Google Scholar 

  46. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138–41.

    Article  PubMed  CAS  Google Scholar 

  47. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274:2057–9.

    Article  PubMed  CAS  Google Scholar 

  48. O’Connell P, Pekkel V, Fuqua SAW, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90:697–703.

    PubMed  CAS  Google Scholar 

  49. Dillon EK, de Boer WB, Papadimitriou JM, et al. Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. Br J Cancer 1997; 76:156–62.

    PubMed  CAS  Google Scholar 

  50. Lakhani SR, Slack DN, Hamoudi RA, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 1996; 74:129–35.

    PubMed  CAS  Google Scholar 

  51. Lizard-Nacol S, Lidereau R, Collin F, et al. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 1995; 55:4416–19.

    PubMed  CAS  Google Scholar 

  52. Lininger RA, Park W-S, Man Y-G, et al. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 1998; 29:1113–18.

    Article  PubMed  CAS  Google Scholar 

  53. Rosenberg CL, Larson PS, Romo JD, et al. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 1997; 28:214–19.

    Article  PubMed  CAS  Google Scholar 

  54. Larson PS, de las Morenas A, Cupples LA, et al. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998; 152:1591–8.

    PubMed  CAS  Google Scholar 

  55. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol 2000; 9:14–19.

    Article  PubMed  CAS  Google Scholar 

  56. Micale MA, Wisscher DW, Gulino SE, et al. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 1994; 25:29–35.

    Article  PubMed  CAS  Google Scholar 

  57. Sneige N, Sahin A, Dinh M, et al. Interphase cytogenetics in mammographically detected breast lesions. Hum Pathol 1996; 27:330–5.

    PubMed  CAS  Google Scholar 

  58. Lundin C, Mertens F. Cytogenetics of benign breast lesions. Breast Cancer Res Treat 1998; 51:1–15.

    Article  PubMed  CAS  Google Scholar 

  59. Dietrich CU, Pandis N, Rizou H, et al. Cytogenetic findings in phyllodes tumors of the breast: karyotypic complexity differentiates between malignant and benign tumours. Hum Pathol 1997; 28:1379–82.

    Article  PubMed  CAS  Google Scholar 

  60. Millikan R, Hulka B, Thor A, et al. p53 mutations in benign breast disease. J Clin Oncol 1995; 13:2293–300.

    PubMed  CAS  Google Scholar 

  61. Kandel RA, Li S-Q, Ozcelik H, et al. p53 protein accumulation and mutations in normal and benign breast tissue. Int J Cancer 2000; 87:73–8.

    Article  PubMed  CAS  Google Scholar 

  62. Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, et al. p53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol 2000; 22:268–74.

    Article  PubMed  CAS  Google Scholar 

  63. Zhu XL, Hartwick W, Rohan T, et al. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Modern Path 1998; 11:1082–8.

    CAS  Google Scholar 

  64. Lalle P, De Latour M, Rio P, et al. Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context Oncogene 1994; 9:437–42.

    PubMed  CAS  Google Scholar 

  65. Kasami M, Vnencak-Jones CL, Manning S, et al. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997; 150:1925–32.

    PubMed  CAS  Google Scholar 

  66. Cummings MC, Aubele M, Mattis A, et al. Increasing chromosome 1 copy number parallels histological progression in breast carcinogenesis. Br J Cancer 2000; 82:1204–10.

    PubMed  CAS  Google Scholar 

  67. Rohan TE, Hartwick W, Miller AB, et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998; 90:1262–9.

    Article  PubMed  CAS  Google Scholar 

  68. Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000; 18:267–74.

    PubMed  CAS  Google Scholar 

  69. Rohan TE, Jain M, Miller AB. A case-cohort study of diet and risk of benign proliferative epithelial disorders of the breast (Canada). Cancer Causes Control 1998; 9:19–27.

    Article  PubMed  CAS  Google Scholar 

  70. Frantz VK, Pickren JW, Melcher GW, et al. Incidence of chronic cystic disease in so-called normal breasts. Cancer 1951; 4:762–83.

    PubMed  CAS  Google Scholar 

  71. Sloss PT, Bennett WA, Clagett OT. Incidence in normal breasts of features associated with chronic cystic mastitis. Am J Pathol 1957; 33: 1181–91.

    PubMed  CAS  Google Scholar 

  72. Sandison AT. An autopsy study of the adult human breast. National Cancer Institute Monograph 8, DHEW PHS. Washington, DC: US GPO, 1962.

    Google Scholar 

  73. Humphrey LJ, Swerdlow M. Histologic changes in clinically normal breasts at postmortem examination. Arch Surg 1966; 92:192–3.

    PubMed  CAS  Google Scholar 

  74. Kramer WM, Rush BF Jr. Mammary duct proliferation in the elderly. A histopathologic study. Cancer 1973; 31:130–7.

    PubMed  CAS  Google Scholar 

  75. Sasano N, Tateno H, Stemmerman GN. Volume and hyperplastic lesions of breasts of Japanese women in Hawaii and Japan. Prev Med 1978; 7:196–204.

    Article  PubMed  CAS  Google Scholar 

  76. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. Cancer 1984; 54:612–15.

    PubMed  CAS  Google Scholar 

  77. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985; 16:796–807.

    PubMed  CAS  Google Scholar 

  78. Bhathal PS, Brown RW, Lesueur GC, et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985; 51:271–8.

    PubMed  CAS  Google Scholar 

  79. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987; 56:814–19.

    PubMed  CAS  Google Scholar 

  80. Sarnelli R, Squartini F. Fibrocystic condition and “at risk” lesions in asymptomatic breasts: morphologic study of postmenopausal women. Clin Exp Obstet Gynecol 1991; 18:271–9

    PubMed  CAS  Google Scholar 

  81. Ory H, Cole P, MacMahon B, et al. Oral contraceptives and reduced risk of benign breast disease. N Engl J Med 1976; 249:419–22.

    Google Scholar 

  82. Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 1978; 108:112–20.

    PubMed  CAS  Google Scholar 

  83. Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981; 113:203–14.

    PubMed  CAS  Google Scholar 

  84. Soini I, Aine R, Laushlati K, et al. Independent risk factors of benign and malignant breast lesions. Am J Epidemiol 1981; 114:507–14.

    PubMed  CAS  Google Scholar 

  85. Kelsey JL. Breast cancer epidemiology: summary and future directions. Epidemiol Rev 1993; 15:256–63.

    PubMed  CAS  Google Scholar 

  86. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997; 19:310–27.

    PubMed  CAS  Google Scholar 

  87. Lance LL. Risk factors for benign breast disease. Am J Epidemiol 1981; 114:606–7.

    PubMed  CAS  Google Scholar 

  88. Parazzini F, La Vecchia C, Franceschi S, et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120:115–22.

    PubMed  CAS  Google Scholar 

  89. Parazzini F, Ferraroni M, La Vecchia C, et al. Smoking habits and risk of benign breast disease. Int J Epidemiol 1991; 20:430–4.

    PubMed  CAS  Google Scholar 

  90. Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Risk factors for fibrocystic disease and its histopathologic components. J Natl Cancer Inst 1985; 75:43–50.

    PubMed  CAS  Google Scholar 

  91. Pastides H, Kelsey JL, Holford TR, et al. An epidemiologic study of fibrocystic breast disease with reference to ductal epithelial atypia. Am J Epidemiol 1985; 121:440–7.

    PubMed  CAS  Google Scholar 

  92. Bright RA, Morrison AS, Brisson J, et al. Histologic and mammographic specificity of risk factors for benign breast disease. Cancer 1989; 64:653–7.

    PubMed  CAS  Google Scholar 

  93. Rohan TE, Cook MG. Alcohol consumption and risk of benign proliferative epithelial disorders of the breast in women. Int J Cancer 1989; 43:631–6.

    PubMed  CAS  Google Scholar 

  94. Rohan TE, Cook MG, Baron JA. Cigarette smoking and benign proliferative epithelial disorders of the breast in women: a case-control study. J Epidemiol Community Health 1989; 43:362–8.

    PubMed  CAS  Google Scholar 

  95. Ingram D, Nottage E, Ng S, et al. Obesity and breast disease: the role of female sex hormones. Cancer 1989; 64:1049–53.

    PubMed  CAS  Google Scholar 

  96. Ingram DM, Nottage E, Roberts T. The role of diet in the development of breast cancer: a case-control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of the breast. Br J Cancer 1991; 64:187–91.

    PubMed  CAS  Google Scholar 

  97. London SJ, Stein EA, Henderson IC, et al. Carotenoids, retinol, and vitamin E and risk of proliferative benign breast disease and breast cancer. Cancer Causes Control 1992; 3:503–12.

    Article  PubMed  CAS  Google Scholar 

  98. Minami Y, Ohuchi N, Taeda Y, et al. Risk factors for benign breast disease according to histopathological type: comparisons with risk factors for breast cancer. Jpn J Cancer Res 1998; 89:116–23.

    PubMed  CAS  Google Scholar 

  99. Hsieh C, Walker AM, Trapido EJ, et al. Age at first birth and breast atypia. Int J Cancer 1984; 33:309–12.

    PubMed  CAS  Google Scholar 

  100. Rohan TE, Jain M, Miller AB. Alcohol consumption and risk of benign proliferative epithelial disorders of the breast: a case-control study. Public Health Nutr 1998; 1:139–45.

    Article  PubMed  CAS  Google Scholar 

  101. Rohan TE. Cigarette smoking and risk of benign proliferative epithelial disorders of the female breast. Eur J Epidemiol 1999; 15:529–35.

    Article  PubMed  CAS  Google Scholar 

  102. Friedenreich C, Bryant H, Alexander F, et al. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000; 29:637–44.

    Article  PubMed  CAS  Google Scholar 

  103. Royal College of General Practitioners. Oral contraceptives and health. London: Pitman Medical, 1974, pp. 25–6.

    Google Scholar 

  104. Ory H, Cole P, MacMahon B, et al. Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 1976; 294:419–22.

    PubMed  CAS  Google Scholar 

  105. Rohan TE, Miller AB. A cohort study of oral contraceptives and risk of benign breast disease. Int J Cancer 1999; 82:191–6.

    Article  PubMed  CAS  Google Scholar 

  106. Vessey MP, Doll R, Sutton PM. Investigation of the possible relationship between oral contraceptives and benign and malignant breast disease. Cancer 1971; 28:1395–9.

    PubMed  CAS  Google Scholar 

  107. Sartwell PE, Arthes FG, Tonascia JA. Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N Engl J Med 1973; 288:551–4.

    PubMed  CAS  Google Scholar 

  108. Kelsey JL, Lindfors KK, White C. Case-control study of the epidemiology of benign breast diseases with reference to oral contraceptive use. Int J Epidemiol 1974; 3:333–40.

    PubMed  CAS  Google Scholar 

  109. Kelsey JL, Holford TR, White C, et al. Oral contraceptives and breast disease. Am J Epidemiol 1978; 107:236–44.

    PubMed  CAS  Google Scholar 

  110. Fasal E, Paffenbarger RS. Oral contraceptives as related to cancer and benign lesions of the breast. J Natl Cancer Inst 1975; 55:767–73.

    PubMed  CAS  Google Scholar 

  111. Nomura A, Comstock GW. Benign breast tumor and estrogenic hormones: a population-based retrospective study. Am J Epidemiol 1976; 103:439–44.

    PubMed  CAS  Google Scholar 

  112. Lees AW, Burns PE, Grace M. Oral contraceptives and breast disease in premenopausal northern Albertan women. Int J Cancer 1978; 22:700–7.

    PubMed  CAS  Google Scholar 

  113. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979; 15:395–405.

    PubMed  CAS  Google Scholar 

  114. Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Oral contraceptive use and fibrocystic breast disease among pre-and postmenopausal women. Am J Epidemiol 1984; 120:87–96.

    PubMed  CAS  Google Scholar 

  115. Parazzini F, La Vecchia C, Franceschi S, et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120:115–22.

    PubMed  CAS  Google Scholar 

  116. Franceschi S, La Vecchia C, Parazzini F, et al. Oral contraceptives and benign breast disease: a case-control study. Am J Obstet Gynecol 1984; 149:602–6.

    PubMed  CAS  Google Scholar 

  117. Rohan TE, L’Abbé KA, Cook MG. Oral contraceptives and risk of benign proliferative epithelial disorders of the breast. Int J Cancer 1992; 50:891–4.

    PubMed  CAS  Google Scholar 

  118. Rautalahti M, Albanes D, Haukka J, et al. Risk factors for histologically confirmed benign breast tumors. Eur J Epidemiol 1994; 10:259–65.

    Article  PubMed  CAS  Google Scholar 

  119. LiVolsi VA, Stadel BV, Kelsey JL, et al. Fibrocystic disease in oral-contraceptive users. N Engl J Med 1978; 299:381–5.

    PubMed  CAS  Google Scholar 

  120. Kampert JB, Wood DA, Paffenbarger RS. Oral contraceptives and breast disease. In: Feig SA, McLelland R (eds) Breast carcinoma. Current diagnosis and treatment. Chicago: Masson, 1983, pp. 597–607.

    Google Scholar 

  121. Pastides H, Kelsey JL, LiVolsi VA, et al. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology. J Natl Cancer Inst 1983; 71:5–9.

    PubMed  CAS  Google Scholar 

  122. Hsieh C-C, Crosson AW, Walker AM, et al. Oral contraceptive use and fibrocystic breast disease of different histologic classifications. J Natl Cancer Inst 1984; 72:285–90.

    PubMed  CAS  Google Scholar 

  123. Jick SS, Walker AM, Jick H. Conjugated estrogens and fibrocystic disease. Am J Epidemiol 1986; 124:746–51.

    PubMed  CAS  Google Scholar 

  124. Nomura A, Comstock GW. Benign breast tumor and estrogenic hormones: a population-based retrospective study. Am J Epidemiol 1976; 103:439–44.

    PubMed  CAS  Google Scholar 

  125. Trapido EJ, Brinton LA, Schairer C, et al. Estrogen replacement therapy and benign breast disease. J Natl Cancer Inst 1984; 73:1101–5.

    PubMed  CAS  Google Scholar 

  126. Berkowitz GS, Kelsey JL, Holford TR, et al. Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women. Am J Epidemiol 1985; 121:238–45.

    PubMed  CAS  Google Scholar 

  127. Pastides H, Najjar MA, Kelsey JL. Estrogen replacement therapy and fibrocystic breast disease. Am J Prev Med 1987; 3:282–6.

    PubMed  CAS  Google Scholar 

  128. Sartwell PE, Arthes FG, Tonascia JA. Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N Engl J Med 1973; 288:551–4.

    PubMed  CAS  Google Scholar 

  129. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290:15–19.

    Google Scholar 

  130. Tzigounis V, Cardamakis E, Ginopoulos P, et al. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormone replacement therapy). Anticancer Res 1996; 16:3997–4000.

    Google Scholar 

  131. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999; 8:123–30.

    PubMed  CAS  Google Scholar 

  132. Berkowitz GS, Kelsey JL, Li Volsi VA, et al. Exogenous hormone use and fibrocystic disease by histopathologic component. Int J Cancer 1984; 34:43–9.

    Google Scholar 

  133. Lubin F, Wax Y, Ron E, et al. Nutritional factors associated with benign breast disease etiology: a case-control study. Am J Clin Nutr 1989; 50:551–6.

    PubMed  CAS  Google Scholar 

  134. Hislop TG, Band PR, Deschamps M, et al. Diet and histologic types of benign breast disease defined by subsequent risk of breast cancer. Am J Epidemiol 1990; 131:263–70.

    PubMed  CAS  Google Scholar 

  135. Rohan TE, Cook MG, Potter JD, et al. A case-control study of diet and benign proliferative epithelial disorders of the breast. Cancer Res 1990; 50:3176–81.

    PubMed  CAS  Google Scholar 

  136. London SJ, Sacks FM, Stampfer MJ, et al. Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Cancer Inst 1993; 85:785–93.

    PubMed  CAS  Google Scholar 

  137. Rohan TE, Jain M, Miller AB. A case-cohort study of diet and risk of benign proliferative epithelial disorders of the breast (Canada). Cancer Causes Control 1998; 9:19–27.

    Article  PubMed  CAS  Google Scholar 

  138. Baghurst PA, Rohan TE. Dietary fibre and risk of benign proliferative epithelial disorders of the breast. Int J Cancer 1995; 63:481–5.

    PubMed  CAS  Google Scholar 

  139. London SJ, Stein EA, Henderson IC, et al. Carotenoids, retinol, and vitamin E and risk of proliferative benign breast disease and breast cancer. Cancer Causes Control 1992; 3:503–12.

    Article  PubMed  CAS  Google Scholar 

  140. Trentham-Dietz A, Newcomb P, Storer BE, et al. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2000; 9:697–703.

    PubMed  CAS  Google Scholar 

  141. Weiss HA, Brinton LA, Brogan D, et al. Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 1996; 73:1298–305.

    PubMed  CAS  Google Scholar 

  142. Longnecker MP, Bernstein L, Paganini-Hill A, et al. Risk factors for in situ breast cancer. Cancer Epidemiol Biomark Prev 1996; 5:961–5.

    CAS  Google Scholar 

  143. Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997; 89:77–82.

    Google Scholar 

  144. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. J Am Med Assoc 1999; 281:2091–7.

    Article  CAS  Google Scholar 

  145. Brinton LA, Hoover R, Fraumeni JF Jr. Epidemiology of minimal breast cancer. J Am Med Assoc 1983; 249:483–7.

    Article  CAS  Google Scholar 

  146. Lambe M, Hsieh C-C, Tsaih S-W, et al. Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J Cancer 1998; 88:330–2.

    Google Scholar 

  147. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54:825–32.

    PubMed  CAS  Google Scholar 

  148. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5:491–500.

    Article  PubMed  CAS  Google Scholar 

  149. Colditz GA, Hankinson SE, Hunter DJ, et al. Use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589–93.

    Article  PubMed  CAS  Google Scholar 

  150. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995; 274:137–42.

    Article  CAS  Google Scholar 

  151. Henrich JB, Kornguth PJ, Viscoli CM, et al. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998; 51:1277–83.

    Article  PubMed  CAS  Google Scholar 

  152. Dubin N, Pasternack BS. Breast cancer screening data in case-control studies. Am J Epidemiol 1984; 120:8–16.

    PubMed  CAS  Google Scholar 

  153. Helvie MA, Hessler C, Frank TS, et al. Atypical hyperplasia of the breast: mammographic appearance and histologic correlation. Radiology 1991; 179:759–64.

    PubMed  CAS  Google Scholar 

  154. Gottardis MM, Lamph WW, Shalinsky DR, et al. The efficacy of 9-cis retionoic acid in experimental models of cancer. Breast Cancer Res Treat 1996; 38:85–96.

    Article  PubMed  CAS  Google Scholar 

  155. Green A, Shilkaitis A, Christov K. 4-(Hydroxyphenyl) retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. Carcinogenesis 1999; 20:1535–40.

    Article  PubMed  CAS  Google Scholar 

  156. Mehta RG, Williamson E, Patel MK, et al. A ligand of peroxisome proliferator-activated receptor g, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92:418–23.

    PubMed  CAS  Google Scholar 

  157. Ip C, Ip MM, Loftus T, et al. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. Cancer Epidemiol Biomarkers Prev 2000; 9:689–96.

    PubMed  CAS  Google Scholar 

  158. Lipkin M, Newmark HL. Vitamin D, calcium and prevention of breast cancer: a review. J Amer Coll Nutr 1999; 18(Suppl):392–7.

    Google Scholar 

  159. Ip C, Thompson HJ, Ganther HE. Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol Biomark Prev 2000; 9:49–54.

    CAS  Google Scholar 

  160. Katdare M, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Res 1998; 5:311–15.

    CAS  Google Scholar 

  161. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999; 84:4017–24.

    Article  PubMed  CAS  Google Scholar 

  162. Ernster VL, Goodson WH, Hunt TK, et al. Vitamin E and benign breast “disease”: a double-blind, randomized clinical trial. Surgery 1985; 97:490–4.

    PubMed  CAS  Google Scholar 

  163. London RS, Sundaram GS, Murphy L, et al. The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol 1985; 65:104–6.

    PubMed  CAS  Google Scholar 

  164. Minton JP, Abou-Issa H, Reiches N, et al. Clinical and biochemical studies on methylxanthine-related fibrocystic breast disease. Surgery 1981; 90:299–304.

    PubMed  CAS  Google Scholar 

  165. Brooks PG, Gart S, Heldfond AJ, et al. Measuring the effect of caffeine restriction on fibrocystic breast disease. J Reprod Med 1981; 26:279–82.

    PubMed  CAS  Google Scholar 

  166. Thomas DB. Epidemiologic and related studies of breast cancer etiology. In: Lilienfeld AM (ed) Reviews in cancer epidemiology, Vol. I. North Holland: Elsevier, 1980, pp. 153–217.

    Google Scholar 

Download references

Authors
  1. Thomas E. Rohan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita A. Kandel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Oncology and Epidemiology, McGill University, Montreal, Quebec, H2W 1S6, Canada

    Eduardo L. Franco MPH, DrPH (Professor, Director) (Professor, Director)

  2. Division of Cancer Epidemiology, McGill University, Montreal, Quebec, H2W 1S6, Canada

    Eduardo L. Franco MPH, DrPH (Professor, Director) (Professor, Director)

  3. Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA

    Thomas E. Rohan MB, BS, PhD (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Rohan, T.E., Kandel, R.A. (2002). Breast. In: Franco, E.L., Rohan, T.E. (eds) Cancer Precursors. Springer, New York, NY. https://doi.org/10.1007/0-387-21605-7_16

Download citation

  • DOI: https://doi.org/10.1007/0-387-21605-7_16

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95188-1

  • Online ISBN: 978-0-387-21605-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation